Library - Scientific articles and publications about the drug Mexidol®.

Registered on ClinicalTrials

Results of an international multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of sequential therapy with ethylmethylhydroxypyridine succinate in patients in the acute and early recovery periods of ischemic stroke (IS)

The results of a cohort -center randomized study of the modulating effect of Mexidol® in the rehabilitation of patients who have undergone acute cerebral failure

The value of mitochondrial dysfunction in stabilization

The results of a multicenter dual blind randomized placebo-controlled clinical study on the assessment of the effectiveness and safety of the drug Mexidol in the treatment of attention deficit syndrome in children (mega)

The results of an international multicenter randomized double-blind-controlled study of evaluating the effectiveness of the effectiveness and safety of consistent therapy of patients with chronic brain ischemia with Mexidol and Mexidol Forte 250 (study of Memo)

The results of a randomized double blind multicenter placebo-controlled in parallel groups of the study and safety of Mexidol with prolonged consistent therapy in patients in the acute and early recovery periods

The results of a cohort -center randomized study of the modulating effect of Mexidol® in the rehabilitation of patients who have undergone acute cerebral failure

The value of mitochondrial dysfunction in stabilization

Brain aging and mechanisms of geroprotection

E.I. CHUKANOVA, A.S. CHUKANOVA

FGAOU in Russian National Research Medical University named after N.I. Pirogov »Ministry of Health of Russia, Moscow, Russia

Place of publication:
NEW THERAPEUTIC JOURNAL "NON NOCERE" / NOVEMBER 2025

Brain aging: molecular targets for geroprotection and prevention strategies

E.I. CHUKANOVA, A.S. CHUKANOVA

FGAOU in Russian National Research Medical University named after N.I. Pirogov »Ministry of Health of Russia, Moscow, Russia

Place of publication:
S.S. Korsakov Journal of Neurology and Psychiatry 2025, Vol. 125, No. 11, pp. 132–139
https://doi.org/10.17116/jnevro2025125111132

Improving the quality of life and the possibility of pathogenetic therapy in adult patients with cerebral palsy

E.A. ANTIPENKO, A.V. SHULYNDIN

Federal State Budgetary Educational Institution of Higher Education "Privolzhsky Research Medical University" of the Ministry of Health of the Russian Federation, Nizhny Novgorod, Russia

Place of publication:
S.S. Korsakov Journal of Neurology and Psychiatry 2025, Vol. 125, No. 10, pp. 75–84
https://doi.org/10.17116/jnevro202512510175

Cognitive dysfunction in children with nervous system diseases: modern approaches to diagnosis and treatment

S.A. NEMKOVA

Federal State Autonomous Educational Institution of Higher Education "N.I. Pirogov Russian National Research Medical University" of the Ministry of Health of the Russian Federation,
Moscow, Russia

Place of publication:
S.S. Korsakov Journal of Neurology and Psychiatry 2025, Vol. 125, No. 10, Issue 2, pp. 69–79
https://doi.org/10.17116/jnevro202512510269

Results of an international multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of sequential therapy with ethylmethylhydroxypyridine succinate in patients in the acute and early recovery periods of ischemic stroke (IS)

Registered on ClinicalTrials

N.A. SHAMALOV ¹ , A.I. FEDIN ² , G.S. RAKHIMBAYEVA ³ , E.S. NURGUZHAEV ⁴ , D.R. KHASANOVA ⁵ , E.Yu. SOLOVIOVA ² , E.V. MELNIKOVA ⁶ , S.N. YANISHEVSKY ⁷ , V.V. MASHIN ⁸ , N.V. PIZOVA ⁹ , I.E. Poverennova ¹⁰ , S.E. CHUPRINA ¹¹ , A.S. AGAFINA ¹² , L.V. ROSHKOVSKA ¹³

¹ Federal Center for Brain and Neurotechnology of the Federal Medical and Biological Agency of the Russian Federation, Moscow, Russia;
² Pirogov Russian National Research Medical University, Moscow, Russia;
³ Tashkent Medical Academy, Tashkent, Uzbekistan;
⁴ Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan;
⁵ Kazan State Medical University, Kazan, Russia;
⁶ Leningrad Regional Center for Medical Rehabilitation, Kommunar, Russia;
⁷ Almazov National Medical Research Center, Saint Petersburg, Russia;
⁸ Ulyanovsk State University, Ulyanovsk, Russia;
⁹ Yaroslavl State Medical University, Yaroslavl, Russia.
^10. Samara Regional Clinical Hospital named after V.D. Seredavin, Samara, Russia;
^11. Voronezh Regional Clinical Hospital No. 1, Voronezh, Russia;
^12. St. Petersburg City Hospital No. 40, St. Petersburg, Russia;
^13. St. Petersburg Alexandrovskaya Hospital, St. Petersburg, Russia

Place of publication:
S.S. Korsakov Journal of Neurology and Psychiatry 2025, Vol. 125, No. 8, Issue 2, pp. 40–53
https://doi.org/10.17116/jnevro202512508240

What you need to know about cognitive impairment

S.R. Shakirzyanova

Place of publication:
NEW THERAPEUTIC JOURNAL "NON NOCERE" SEPTEMBER 2025

Study of drug interactions between Mexidol and thrombolytic drugs

A.V. SHCHULKIN, I.V. CHERNYKH, Yu.V. ABALENIKHINA, M.V. GATSANOGA, M.M. GRADINAR,
P.D. ANANYEVA, E.N. YAKUSHEVA

FGBOU in the Ryazan State Medical University named after Acad. I.P. Pavlova "of the Ministry of Health of Russia, Ryazan, Russia

Place of publication:
S.S. Korsakov Journal of Neurology and Psychiatry 2025, Vol. 125, No. 9, pp. 139–144
https://doi.org/10.17116/jnevro2025125091139

Potential of antioxidant neuroretinoprotection in the treatment of primary open-angle glaucoma

E.A. EGOROV ¹ , A.V. KUROEDOV ¹ , ² , N.A. GAVRILOVA ³ , A.E. YAVORSKY ⁴ , E.A. GORNOSTAYEVA ⁵

¹ Pirogov Russian National Medical Research University, Moscow, Russia;
² Mandryka Central Military Clinical Hospital,
³ Russian University of Medicine, Moscow, Russia;
⁴ V.P. Vykhodtsev Clinical Ophthalmological Hospital, Omsk, Russia;
⁵ Zrenie Diagnostic Center, Saint Petersburg, Russia

Place of publication:
Bulletin of Ophthalmology 2025, Vol. 141, No. 4, pp. 49–59
https://doi.org/10.17116/oftalma202514104149

Attention Deficit Hyperactivity Disorder - Clinical Manifestations from Child to Adult

Authors:
L. S. Chutko, Professor, Doctor of Medical Sciences, Head of the Laboratory of Correction of Mental Development and Adaptation, Head of the Center for Behavioral Neurology of the N.P. Bekhtereva Institute of the Human Brain of the Russian Academy of Sciences, Professor of the Department of Family Medicine of the Faculty of Preparatory and Continuing Professional Education of the Federal State Budgetary Educational Institution of Higher Education St. Petersburg State Pediatric Medical University of the Ministry of Health of the Russian Federation, St. Petersburg, Russia

E. A. Yakovenko, Ph.D., researcher at the Institute of the Human Brain named after. N.P. Bekhtereva Russian Academy of Sciences, St. Petersburg, Russia

S. Yu. Surushkina, neurologist, PhD, research fellow at the N.P. Bekhtereva Institute of the Human Brain of the Russian Academy of Sciences, St. Petersburg, Russia

The main mechanisms of development of cognitive impairment

A.N. BOGOLEPOVA

Federal State Autonomous Educational Institution of Higher Education “N.I. Pirogov Russian National Research Medical University” of the Ministry of Healthcare of the Russian Federation
(Pirogov University), Moscow, Russia;
Federal Center for Brain and Neurotechnology of the Federal Medical and Biological Agency of Russia, Moscow, Russia

Known and new ideas about the mechanism of action and spectrum of effects of Mexidol

1Federal Research Center for Original and Promising Biomedical and Pharmaceutical
Technologies, Moscow, Russia;
2Volga Region Research Medical University of the Ministry of Health of the Russian Federation, Nizhny Novgorod, Russia

The effect of Mexidol on improving quality of life parameters and functional state of the kidneys as part of complex therapy for cognitive impairment in comorbid patients with microalbuminuria against the background of arterial hypertension and type 2 diabetes mellitus

V.V. TOLKACHEVA, L.V. KARAPETYAN, L.G. EZHOVA, N.I. KHUTSISHVILI, N.I. KONTAREVA,
S.A. GALOCHKIN, E.R. KAZAKHMEDOV, J.D. KOBALAVA

FGAOU in Russian University of Friendship of Peoples named after Patrice Lumumba, Moscow, Russia

Arterial hypertension - oxidative stress as a pathogenetic target of treatment of chronic cerebrovascular insufficiency

Authors:

Chukanova E.I., Chukanova A.S. , Andrianov D.D.

FGAOU in Russian National Research Medical University named after N.I. Pirogov "of the Ministry of Health of Russia
(Pirogov University), Moscow, Russia

Oxidizing stress in pathogenesis of chronic headache

Author:
Fedin A.I.

FGAOU in Russian National Research Medical University named after N.I. Pirogov »Ministry of Health of Russia, Moscow, Russia

Cognitive disorders in patients with arterial hypertension

Author:

Vladimir Vladimirovich Zakharov D.M.N., Professor of the Department of Nervous Diseases and Neurosurgery, FGAOU in the First Moscow Medical University named after THEM. Sechenov "Ministry of Health of Russia (Sechenov University), Moscow, Russia

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2024, T. 124, No. 4, Issue. 2

Cognitive disorders in a patient with arterial hypertension in the practice of the therapist. Questions and answers

Authors:

Olga Dmitrievna Ostroumova, MD, professor, head of the department of therapy and polymorbid pathology named after Acad. M.S. VOLISY FSBEI DPO RANMO of the Ministry of Health of Russia, Moscow, Russia

Natalya Andreevna Shatalova, assistant department of therapy and polymorbid pathology named after Acad. M.S. VOLISY FSBEI DPO RANMO of the Ministry of Health of Russia, Moscow, Russia

Cognitive disorders in patients with arterial hypertension

Journal of neurology and psychiatry named after S.S. Korsakova, 2024

1 2 3 … 14 »